Payment overview · 2025
General Payments
$70.66
3 reported records · 3 companies
Healthcare provider profile · identity verified
Darrell L Hutchison, MD
Allopathic & Osteopathic Physicians|General Practice · CORNING, AR · NPI 1962441436
Verified facts
What the public records show
CMS Open Payments records show Darrell L Hutchison, MD received $70.66 in general payments during 2025 across 3 reported records.
Seqirus USA Inc accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $30.21 | 42.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.68 | 30.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.77 | 26.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.66 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 52 |
| Potassium Chloride | Potassium Chloride | 234 | 37 |
| Omeprazole | Omeprazole | 229 | 32 |
| Gabapentin | Gabapentin | 221 | 35 |
| Lisinopril | Lisinopril | 212 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 28 |
| Furosemide | Furosemide | 174 | 31 |
| Sertraline Hcl | Sertraline Hcl | 169 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 28 |
| Metformin Hcl | Metformin Hcl | 149 | 27 |
| Famotidine | Famotidine | 138 | 21 |
| Alprazolam | Alprazolam | 119 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 18 |
| Jardiance | Empagliflozin | 111 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | 15 |
| Tramadol Hcl | Tramadol Hcl | 100 | 22 |
| Carvedilol | Carvedilol | 98 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 16 |
| Allopurinol | Allopurinol | 96 | 11 |
| Simvastatin | Simvastatin | 94 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 18 |
| Montelukast Sodium | Montelukast Sodium | 88 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 17 |
| Glipizide Er | Glipizide | 84 | 13 |
| Pregabalin | Pregabalin | 80 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 12 |
| Meloxicam | Meloxicam | 69 | 11 |
| Ozempic | Semaglutide | 69 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | suppressed |
| Eliquis | Apixaban | 64 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | suppressed |
| Ezetimibe | Ezetimibe | 57 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | 11 |
| Atenolol | Atenolol | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Diazepam | Diazepam | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.66 · 3 records | Seqirus USA Inc | FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error